By GCNC Intelligence Unit | Bogotá & São Paulo
South America’s cannabis sector continues to position itself as a primary global hub for low-cost, high-quality cultivation and pharmaceutical extract production. As domestic markets mature and international demand for medical-grade supply increases, key producing nations across the continent are refining their regulatory structures to bolster export competitiveness while gradually expanding patient access locally.
A major focus across the region centers on navigating foreign regulatory barriers and achieving international certifications, such as EU-GMP and local INVIMA standards. While countries like Colombia and Uruguay continue to lead in bulk extract exports and pharmaceutical-grade supply, markets like Brazil represent the continent’s largest domestic patient base, driven by evolving health authority guidelines and expanding pharmacy distribution. For regional operators, aligning cultivation standards with global import requirements remains the defining factor for commercial scale.
Looking ahead through 2026, South America’s trade trajectory will be shaped by cross-border commercial agreements, expanding regional patient access, and increased processing capabilities. Companies that integrate supply chain traceability with high-level compliance will be best positioned to supply both expanding domestic markets and high-value international destinations.
